Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer 30-05-2025, 17:00

Quantexa Reaches Centaur Status, Surpassing $100 Million ARR 29-10-2024, 07:01

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth 29-01-2025, 19:00